The latest price target for Myriad Genetics (NASDAQ:MYGN) was reported by Stephens & Co. on January 16, 2025. The analyst firm set a price target for $20.00 expecting MYGN to rise to within 12 months (a possible 59.11% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Myriad Genetics (NASDAQ:MYGN) was provided by Stephens & Co., and Myriad Genetics reiterated their equal-weight rating.

The last upgrade for Myriad Genetics Inc happened on May 8, 2024 when Leerink Partners raised their price target to $35. Leerink Partners previously had a market perform for Myriad Genetics Inc.

The last downgrade for Myriad Genetics Inc happened on December 9, 2024 when Leerink Partners changed their price target from $30 to $21 for Myriad Genetics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on January 16, 2025 so you should expect the next rating to be made available sometime around January 16, 2026.

While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a reiterated with a price target of $20.00 to $20.00. The current price Myriad Genetics (MYGN) is trading at is $12.57, which is out of the analyst’s predicted range.